Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment
The FDA approved Zoetis' Convenia RTU for Dogs (cefovecin injectable suspension), a more concentrated formulation that delivers up to 14 days of antibiotic treatment in a single injection for bacterial skin infections in dogs. The new formulation is bioequivalent to the original Convenia, approved in 2008, and is designed to make single-injection treatment practical for medium and large breeds where volume constrained the prior product.
Key figures
- Drug Name
- Convenia RTU for Dogs (cefovecin injectable suspension)
- Phase Of Trial
- approved (bioequivalent to Convenia)
- Expected Availability
- Q1 2027
- Treatment Duration Days
- 14
- Single Injection Resolution Rate
- 86%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.